PMID- 27318987
OWN - NLM
STAT- MEDLINE
DCOM- 20171211
LR  - 20231213
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 233
IP  - 15-16
DP  - 2016 Aug
TI  - Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in 
      zebrafish: role of serotonin 5HT2-type receptors.
PG  - 3031-9
LID - 10.1007/s00213-016-4352-4 [doi]
AB  - RATIONALE: The synthetic phenethylamines are recreational drugs known to produce 
      psychostimulant effects. However, their abuse potential has not been widely 
      studied. OBJECTIVES: Here, we investigated the rewarding and the hallucinatory 
      effects of 2,5-dimetoxy-4-bromo-amphetamine hydrobromide (DOB) and 
      para-methoxyamphetamine (PMA) in comparison with the classical 
      3,4-methylenedioxymethamphetamine (MDMA). In addition, the role of serotonin 
      5-HT2-like receptor on the abovementioned effects was evaluated. METHODS: 
      Zebrafish were intramuscularly (i.m.) treated with a wide range of doses of DOB 
      (0.1-20 mg/kg), PMA (0.0005-2 mg/kg), or MDMA (0.5-160 mg/kg). Animals were 
      submitted to a conditioned place preference (CPP) task, to investigation of the 
      rewarding properties, and to the evaluation of hallucinatory behavior in terms of 
      appearance of a trance-like behavior. The serotonin 5-HT2 subtype receptor 
      antagonist ritanserin (0.025-2.5 mg/kg) in association with the maximal effective 
      dose of MDMA, DOB, and PMA was given i.m., and the effect on CPP or hallucinatory 
      behavior was evaluated. RESULTS: MDMA and its derivatives exhibited CPP in a 
      biphasic fashion, being PMA the most potent. This effect was accompanied, for DOB 
      (2 mg/kg) and PMA (0.1 mg/kg), by a trance-like hallucinatory behavior. MDMA at a 
      high dose as 160 mg/kg did not induce any hallucinatory behavior. Ritanserin 
      significantly blocked the rewarding and hallucinatory effects suggesting the 
      involvement of serotonin 5HT2 subtype receptor. CONCLUSION: Collectively, these 
      findings demonstrate for the first time that the rewarding properties of DOB and 
      PMA are accompanied by hallucinatory behavior through a serotonergic system and 
      reinforce zebrafish as an emerging experimental model for screening new 
      hallucinogens.
FAU - Ponzoni, Luisa
AU  - Ponzoni L
AD  - Department of Medical Biotechnology and Translational Medicine (BIOMETRA), 
      Universita degli Studi di Milano, Milan, Italy.
FAU - Braida, Daniela
AU  - Braida D
AD  - Department of Medical Biotechnology and Translational Medicine (BIOMETRA), 
      Universita degli Studi di Milano, Milan, Italy.
FAU - Sala, Mariaelvina
AU  - Sala M
AD  - Department of Medical Biotechnology and Translational Medicine (BIOMETRA), 
      Universita degli Studi di Milano, Milan, Italy. mariaelvina.sala@unimi.it.
AD  - Institute of Neuroscience, Consiglio Nazionale delle Ricerche (CNR), Milan, 
      Italy. mariaelvina.sala@unimi.it.
AD  - Institute of Neuroscience, Consiglio Nazionale delle Ricerche, and Department of 
      Medical Biotechnology and Translational Medicine (BIOMETRA), Universita degli 
      Studi di Milano, Via Vanvitelli 32, 20129, Milan, Italy. 
      mariaelvina.sala@unimi.it.
LA  - eng
PT  - Journal Article
DEP - 20160618
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Amphetamines)
RN  - 0 (Hallucinogens)
RN  - 0 (Receptors, Serotonin, 5-HT2)
RN  - 0 (Serotonin 5-HT2 Receptor Antagonists)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 145TFV465S (Ritanserin)
RN  - 15588-95-1 (DOM 2,5-Dimethoxy-4-Methylamphetamine)
RN  - 32156-26-6 (2,5-dimethoxy-4-bromoamphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - OVB8F8P39Q (4-methoxyamphetamine)
SB  - IM
EIN - Psychopharmacology (Berl). 2016 Dec;233(23-24):4011. Daniela, Braida [corrected 
      to Braida, Daniela]. PMID: 27665759
MH  - DOM 2,5-Dimethoxy-4-Methylamphetamine/*analogs & derivatives/pharmacology
MH  - Amphetamines/*pharmacology
MH  - Animals
MH  - Behavior, Animal/*drug effects
MH  - Conditioning, Psychological/drug effects
MH  - Female
MH  - Hallucinogens/*pharmacology
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Receptors, Serotonin, 5-HT2/*metabolism
MH  - Reinforcement, Psychology
MH  - Reward
MH  - Ritanserin/pharmacology
MH  - Serotonin 5-HT2 Receptor Antagonists/pharmacology
MH  - Serotonin Receptor Agonists/*pharmacology
MH  - Zebrafish
OTO - NOTNLM
OT  - *Conditioned place preference
OT  - *DOB
OT  - *Hallucinogens
OT  - *PMA
OT  - *Phenethylamines
OT  - *Trance-like
EDAT- 2016/06/20 06:00
MHDA- 2017/12/12 06:00
CRDT- 2016/06/20 06:00
PHST- 2016/02/19 00:00 [received]
PHST- 2016/05/31 00:00 [accepted]
PHST- 2016/06/20 06:00 [entrez]
PHST- 2016/06/20 06:00 [pubmed]
PHST- 2017/12/12 06:00 [medline]
AID - 10.1007/s00213-016-4352-4 [pii]
AID - 10.1007/s00213-016-4352-4 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2016 Aug;233(15-16):3031-9. doi: 
      10.1007/s00213-016-4352-4. Epub 2016 Jun 18.